Top

Journal of Gastrointestinal Surgery

Published in:

01-08-2008 | original article

Borrmann Type IV: An Independent Prognostic Factor for Survival in Gastric Cancer

Authors: Ji Yeong An, Tae Ho Kang, Min Gew Choi, Jae Hyung Noh, Tae Sung Sohn, Sung Kim

Published in: Journal of Gastrointestinal Surgery | Issue 8/2008

Abstract

Background

Borrmann type IV gastric cancer has a poorer prognosis than other gastric carcinomas. This study compared the clinicopathological features of Borrmann type IV gastric cancer with those of other types of cancer and examined the significance of a Borrmann type IV carcinoma as a prognostic factor after gastrectomy.

Methods

The clinicopathological features, tumor–node–metastasis (TNM) stage, and survival rates of 4,191 advanced gastric cancer patients, who had undergone a gastrectomy at the Samsung Medical Center between 1995 and 2005, were reviewed.

Results

Borrmann type IV gastric cancer was found to be associated with more advanced and unfavorable clinicopathological features at diagnosis than the other cancers. The 5-year survival rate of the patients with Borrmann type IV cancer was 27.6%. In contrast, the 5-year survival rate of patients with the other types of cancer was 61.2%. The 5-year survival rate for each stage of Borrmann type IV gastric cancer and the other type gastric cancer was 61.0% and 88.8% for stage Ib (P < 0.001), 49.8% and 76.1% for stage II (P < 0.001), 36.4% and 55.1% for stage IIIa (P < 0.001), 15.2% and 38.5% for stage IIIb (P = 0.001), and 10.2% and 20.1% for stage IV (P = 0.008), respectively. Multivariate analyses revealed a Borrmann type IV carcinoma, the surgical extent, curability, tumor stage, including T, N, and M status, and adjuvant therapy to be independent prognostic factors for survival.

Conclusion

A Borrmann type IV carcinoma has unique clinicopathological features compared with other types of gastric carcinomas and is an important independent prognostic factor.

Kwon SJ, Lee GJ. Clinicopathologic characteristics of Borrmann type IV gastric cancer. J Korean Surg Soc 2003;64(2):127–133.

Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg 2002;72(10):739–742.PubMedCrossRef

Otsuji E, Kuriu Y, Okamoto K, Ochiai T, Ichikawa D, Hagiwara A, Yamagishi H. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 2004;188(3):327–332.PubMedCrossRef

Yook JH, Oh ST, Kim BS. Cliniopathological analysis of Borrmanntype IV gastric cancer. Cancer Res Treat 2005;37:87–91.CrossRef

Kodera Y, Yamamura Y, Ito S, Kanemitsu Y, Shimizu Y, Hirai T, Yasui K, Kato T. Is Borrmann type IV gastric carcinoma a surgical disease? An old problem revisited with reference to the result of peritoneal washing cytology. J Surg Oncol 2001;78(3):175–181. (discussion 181–172).PubMedCrossRef

Hamy A, Letessier E, Bizouarn P, Paineau J, Aillet G, Mirallie E, Visset J. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg 1999;84(4):337–343.PubMed

Koyama T, Yashiro M, Inoue T, Nishimura S, Hirakawa YSCK. TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 2000;16(2):355–362.PubMed

Mahara K, Kato J, Terui T, Takimoto R, Horimoto M, Murakami T, Mogi Y, Watanabe N, Kohgo Y, Niitsu Y. Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br J Cancer 1994;69(4):777–783.PubMed

Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC, Yang JM. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol 2002;8(6):987–993.PubMed

10.

Shino Y, Watanabe A, Yamada Y, Tanase M, Yamada T, Matsuda M, Yamashita J, Tatsumi M, Miwa T, Nakano H. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995;76(11):2193–2201.PubMedCrossRef

11.

Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005;96(6):323–332.PubMedCrossRef

12.

Tanigawa N, Amaya H, Matsumura M, Lu C, Iki M. Association between tumor angiogenesis and Borrmann type 4 carcinomas of the stomach. Oncology 1998;55(5):461–467.PubMedCrossRef

13.

Otsuji E, Yamaguchi T, Sawai K, Sakakura C, Okamoto K, Takahashi T. Regional lymph node metastasis as a predictor of peritoneal carcinomatosis in patients with Borrmann type IV gastric carcinoma. Am J Gastroenterol 1999;94(2):434–437.PubMedCrossRef

14.

Ryu JH, Yook JH, Kim BS, Oh ST, Jung ST, Choi WY. Clinicopathologic characteristics and prognostic factors of long-term survivors of Borrmann type 4 gastric cancer. Korean J Gastroenterol 2003;41:9–14.

15.

Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 2004;10(14):4885–4892.PubMedCrossRef

16.

Sasaki T, Koizumi W, Tanabe S, Higuchi K, Nakayama N, Saigenji K. TS-1 as first-line therapy for gastric linitis plastica: historical control study. Anticancer Drugs 2006;17(5):581–586.PubMedCrossRef

17.

Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006;131(5):1530–1541.PubMedCrossRef

18.

Akamo Y, Takeyama H, Funahashi H, Yamamori Y, Yamamoto M, Teranishi F, Manabe T. Efficacy of intraperitoneal chemotherapy for advanced Borrmann type IV gastric carcinoma. Gan To Kagaku Ryoho 2002;29(12):2184–2187.PubMed

19.

Kunisaki C, Shimada H, Nomura M, Matsuda G, Otsuka Y, Ono H, Akiyama H. Therapeutic strategy for scirrhous type gastric cancer. Hepatogastroenterology 2005;52(61):314–318.PubMed

20.

Ikeguchi M, Yamamoto O, Kaibara N. Management protocol for scirrhous gastric cancer. In Vivo 2004;18(5):577–580.PubMed

Title: Borrmann Type IV: An Independent Prognostic Factor for Survival in Gastric Cancer
Authors: Ji Yeong An
Tae Ho Kang
Min Gew Choi
Jae Hyung Noh
Tae Sung Sohn
Sung Kim
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 8/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0516-9

At a glance: The STEP trials

Springer Medicine

Borrmann Type IV: An Independent Prognostic Factor for Survival in Gastric Cancer

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2008

Acute Diverticulitis of the Left Colon: Value of the Initial CT and Timing of Elective Colectomy

Laparoscopic Repair of a Giant Hiatus Hernia—How I Do It

Interval Period Tumor Progression: Does Delayed Hepatectomy Detect Occult Metastases in Synchronous Colorectal Liver Metastases?

Survival of Patients with Synchronous and Metachronous Colorectal Liver Metastases—is there a Difference?

Small Bowel Volvulus Diagnosed by the CT “Whirl Sign”

Targeted Suppression of β-Catenin Blocks Intestinal Adenoma Formation in APC Min Mice